SS-31 (Elamipretide): The Mitochondrial Peptide That Got an FDA Approval — and Failed Its Biggest Trials
SS-31 binds cardiolipin to repair mitochondrial bioenergetics. It is now FDA-approved for Barth syndrome, but its heart-failure and myopathy trials failed.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13A genuine FDA-approved mitochondrial drug (cardiolipin-targeting) — but approved only for ultra-rare Barth syndrome on a provisional surrogate endpoint; its large heart-failure and general mitochondrial-myopathy trials failed. The mechanism is real; broad efficacy is not established.
Well-validated cardiolipin-binding mechanism: cristae stabilisation, improved oxidative phosphorylation, reduced ROS.
Supportive animal data (canine HFrEF, rat remodelling), but the broad human translation failed.
Multiple RCTs (MMPOWER-1/2/3, PROGRESS-HF, TAZPOWER) — but the large heart-failure and general-myopathy trials failed; only ultra-rare Barth syndrome was positive.
Proven benefit only in ultra-rare Barth syndrome (provisional, surrogate endpoint); negative in heart failure and general mitochondrial myopathy.
Tolerability characterised across RCTs (mainly injection-site reactions); long-term data thin (~8–10 patients to 168 weeks).
FDA-approved (FORZINITY, accelerated, 2025) — but for Barth syndrome only, on a surrogate endpoint.
High confidence in the evidence picture itself: real mechanism, failed broad trials, one narrow approved use.
An approved prescription drug (Barth only); broad use is off-label, and grey-market ‘SS-31’ is not the approved product.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A genuine FDA-approved mitochondrial drug (cardiolipin-targeting) — but approved only for ultra-rare Barth syndrome on a provisional surrogate endpoint; its large heart-failure and general mitochondrial-myopathy trials failed.
Safety snapshot
Tolerability was characterised across trials (mainly injection-site reactions); long-term data are thin, and efficacy is unproven outside Barth syndrome.
Regulatory & legality
An approved prescription drug for Barth syndrome only; broad 'mito-support' use is off-label, and grey-market 'SS-31' is not the approved product.
Where claims can exceed the evidence
The mechanism is real, but broad mitochondrial/fatigue/longevity benefit is not established — the broad-indication trials were negative.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
SS-31 — known in the clinic as elamipretide, and previously as MTP-131 or Bendavia — is unusual among "research peptides". Most compounds in this space rest on animal data and forum reports. SS-31 instead has a genuine pharmaceutical pedigree: it was developed by Stealth BioTherapeutics, ran through multiple registrational human trials, and in September 2025 became an FDA-approved drug [10][12].
That is the good news. The complicated news is that the approval is for one ultra-rare genetic disease — Barth syndrome — and the two largest, most rigorous trials of SS-31 in the conditions people actually talk about (heart failure and general mitochondrial myopathy) failed their primary endpoints [4]. So the honest verdict is "moderate" evidence: real, well-conducted human science, a real drug approval, but a sharp gap between what the mechanism promises and what the broad clinical data deliver.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
5-Amino-1MQ: The NNMT Inhibitor Behind the "Fat-Loss Peptide" Hype
5-Amino-1MQ is a small-molecule NNMT inhibitor with promising mouse and cell data for fat loss and muscle ageing — but zero human trials and no approval.
AICAR: The Original "Exercise in a Pill" — What the Evidence Actually Shows
AICAR is the prototype AMPK-activating exercise mimetic. The endurance hype rests entirely on mice; the only positive human data are from heart surgery.
Epithalon (Epitalon): The Telomerase Peptide, Examined
A clear-eyed look at Epitalon, the pineal tetrapeptide pitched as a telomerase activator — what the evidence actually shows, and why it is weaker than the hype suggests.
MOTS-c: The Mitochondrial "Exercise Mimetic" Peptide — What the Evidence Actually Shows
A clear-eyed look at MOTS-c: strong mechanistic and rodent data for AMPK activation and insulin sensitivity, but human efficacy of the injected peptide is unproven.